No-carrier-added (18F)-N-methylspiroperidol

Title: No-carrier-added (18F)-N-methylspiroperidol

Full Record
Other Related Research

Abstract

There is disclosed a radioligand labeled with a positron emitting radionuclide suitable for dynamic study in living humans with positron emission transaxial tomography. [.sup.18 F]-N-methylspiroperidol, exhibiting extremely high affinity for the dopamine receptors, provides enhanced uptake and retention in the brain concomitant with reduced radiation burden. These characteristics all combine to provide [.sup.18 F]-N-methylspiroperidol as a radioligand superior to known radioligands for mapping dopamine receptors in normal and disease states in the living brain. Additionally, a new synthetic procedure for this material is disclosed.

Inventors:

Shiue, Chyng-Yann ^[1]; Fowler, Joanna S. ^[2]; Wolf, Alfred P. ^[3]

(East Setauket, NY)
(Bellport, NY)
(Setauket, NY)

Issue Date:: 1993-01-01

Research Org.:: ASSOC UNIVERSITIES INC

OSTI Identifier:: 875158

Patent Number(s):: H1209

Assignee:: United States of America as represented by United States (Washington, DC) BNL

DOE Contract Number:: AC02-76CH00016

Resource Type:: Patent

Country of Publication:: United States

Language:: English

Subject:: no-carrier-added; 18f; -n-methylspiroperidol; disclosed; radioligand; labeled; positron; emitting; radionuclide; suitable; dynamic; study; living; humans; emission; transaxial; tomography; 18; exhibiting; extremely; affinity; dopamine; receptors; provides; enhanced; uptake; retention; brain; concomitant; reduced; radiation; burden; characteristics; combine; provide; superior; radioligands; mapping; normal; disease; additionally; synthetic; procedure; material; positron emission; provides enhanced; dopamine receptor; transaxial tomography; emission transaxial; emitting radionuclide; dynamic study; living human; living humans; /424/999/

Citation Formats


                    Shiue, Chyng-Yann, Fowler, Joanna S., and Wolf, Alfred P. No-carrier-added (18F)-N-methylspiroperidol.  United States: N. p., 1993. 
        Web.

Copy to clipboard


                    Shiue, Chyng-Yann, Fowler, Joanna S., & Wolf, Alfred P. No-carrier-added (18F)-N-methylspiroperidol.  United States.

Copy to clipboard


                    Shiue, Chyng-Yann, Fowler, Joanna S., and Wolf, Alfred P. Fri .  
        "No-carrier-added (18F)-N-methylspiroperidol".  United States.  https://www.osti.gov/servlets/purl/875158.

Copy to clipboard


                    
@article{osti_875158,

  title        = {No-carrier-added (18F)-N-methylspiroperidol},

  author       = {Shiue, Chyng-Yann and Fowler, Joanna S. and Wolf, Alfred P.},

  abstractNote = {There is disclosed a radioligand labeled with a positron emitting radionuclide suitable for dynamic study in living humans with positron emission transaxial tomography. [.sup.18 F]-N-methylspiroperidol, exhibiting extremely high affinity for the dopamine receptors, provides enhanced uptake and retention in the brain concomitant with reduced radiation burden. These characteristics all combine to provide [.sup.18 F]-N-methylspiroperidol as a radioligand superior to known radioligands for mapping dopamine receptors in normal and disease states in the living brain. Additionally, a new synthetic procedure for this material is disclosed.},

  doi          = {},

  journal      = {},
number       = ,

  volume       = ,

  place        = {United States},

  year         = {1993},

  month        = {1}

}

Copy to clipboard

Patent:

View Patent

Save / Share:

Export Metadata

Save to My Library

Similar records in DOE Patents and OSTI.GOV collections:

No-carrier-added (18F)-N-methylspiroperidol

Patent Shiue, Chyng-Yann; Fowler, Joanna S.; Wolf, Alfred P.

There is disclosed a radioligand labeled with a positron emitting radionuclide suitable for dynamic study in living humans with positron emission transaxial tomography. [.sup.18 F]-N-methylspiroperidol, exhibiting extremely high affinity for the dopamine receptors, provides enhanced uptake and retention in the brain concomitant with reduced radiation burden. These characteristics all combine to provide [.sup.18 F]-N-methylspiroperidol as a radioligand superior to known radioligands for mapping dopamine receptors in normal and disease states in the living brain. Additionally, a new synthetic procedure for this material is disclosed.
Full Text Available
No-carrier-added (/sup 18/F)-N-methylspiroperidol

Patent Shiue, C.Y.; Fowler, J.S.; Wolf, A.P.

The present invention is directed to the synthesis of a radioligand, labeled with a positron emitting radionuclide which is suitable for dynamic studies in humans using positron emission transaxial tomography. No-carrier-added (NCA) (/sup 18/F)-N-methylspiroperiodl is prepared from four different sustrates: p-nitrobenzonitrile, cyclopropyl p-nitrophenyl ketone, p-cyclopropanoyl-N,N,N-trimethylanilinium iodide and p-cyclopropanoyl-N,N,N-trimethylanilinium perchlorate. The process for the production of NCA (/sup 18/F)-N-methylspiroperidol is a nucleophilic aromatic substitution reaction. Furthermore, the compound of this invention is shown to be effective as a new drug of choice for in vivo examination of dopamine binding sites in a human brain. In particular, this drug is primarily usefulmore »« less
No-carrier-added [.sup.18 F]-N-fluoroalkylspiroperidols

Patent Shiue, Chyng-Yann (East Setauket, NY); Wolf, Alfred P. (Setauket, NY); Bai, Lan-Qin (Upton, NY); ...

There is disclosed radioligands labeled with the position emitting radionuclide [.sup.18 F] suitable for dynamic study in living humans with position emission transaxial tomography. These new [.sup.18 F]-N-fluoroalkylspiroperidols, wherein the alkyl group contains from 2-6 carbon atoms, exhibit extremely high affinity for the dopamine receptors and provide enhanced uptake and retention in the brain concomitant with reduced radiation burden. These characteristics all combine to make these new radioligands useful for mapping dopamine receptors in normal and disease states in the living brain. Additionally, a new synthetic procedure for these radioligands as well as a new procedure for preparing the radiolabeledmore »« less
Full Text Available
No-carrier-added [1.sup.11 c]putrescine

Patent McPherson, Daniel W. (Baltimore, MD); Fowler, Joanna S. (Bellport, NY); Wolf, Alfred P. (Setauket, NY)

The invention relates to a new radiolabeled imaging agent, no-carrier-added [1-.sup.11 C]putrescine, and to the use of this very pure material as a radiotracer with positron emission tomography for imaging brain tumors. The invention further relates to the synthesis of no-carrier-added [1-.sup.11 C]putrescine based on the Michael addition of potassium .sup.11 C-labeled cyanide to acrylonitrile followed by reduction of the .sup.11 C-labeled dinitrile. The new method is rapid and efficient and provides radiotracer with a specific activity greater than 1.4 curies per millimol and in a purity greater than 95%.
Full Text Available
No-carrier-added (NCA) aryl (18E) fluorides via the nucleophilic aromatic substitution of electron rich aromatic rings

Patent Ding, Yu-Shin (Central Islip, NY); Fowler, Joanna S. (Bellport, NY); Wolf, Alfred P. (Setauket, NY)

A method for synthesizing no-carrier-added (NCA) aryl [.sup.18 F] fluoride substituted aromatic aldehyde compositions bearing an electron donating group is described. The method of the present invention includes the step of reacting aromatic nitro aldehydes having a suitably protected hydroxyl substitutent on an electron rich ring. The reaction is The U.S. Government has rights in this invention pursuant to Contract Number DE-AC02-76CH00016, between the U.S. Department of Energy and Associated Universities Inc.
Full Text Available

Similar Records